Endotoxin Neutralization as a Biomonitor for HIV Disease Progression

Information

  • Research Project
  • 8790322
  • ApplicationId
    8790322
  • Core Project Number
    R43AI114445
  • Full Project Number
    1R43AI114445-01
  • Serial Number
    114445
  • FOA Number
    PA-13-234
  • Sub Project Id
  • Project Start Date
    9/1/2014 - 11 years ago
  • Project End Date
    2/28/2015 - 10 years ago
  • Program Officer Name
    SHARP, GERALD B.
  • Budget Start Date
    9/1/2014 - 11 years ago
  • Budget End Date
    2/28/2015 - 10 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/28/2014 - 11 years ago
Organizations

Endotoxin Neutralization as a Biomonitor for HIV Disease Progression

DESCRIPTION (provided by applicant): Endotoxin neutralization in human plasma is an excellent indicator of chronic immune activation, which is the most accurate predictor of mortality in HIV. Recently we developed an assay using endotoxin neutralization as an indicator of bacterial translocation. This assay is accurate in discriminating control patients from those with inflammatory bowel disease in addition to indicating disease severity. We propose to adapt our endotoxin neutralization assay for the evaluation of HIV disease severity and progression. In the 6 month Phase I part of the SBIR project, we will (1) collect plasma from 20 19-50 year old HIV-positive males and an equivalent number of demographically similar HIV-negative male subjects and test for viral load and CD4+ T cell count, (2) measure the levels of specific plasma markers indicative of bacterial translocation, immune system activation and/or inflammatory response, and (3) measure immune activation using our endotoxin neutralization biomarker monitor system. Once a neutralization profile of each sample is established, Pearson correlation will be used to determine the relationship between endotoxin neutralization and all factors established in the first two aims. Student's T-test will be used to determine statistical significance between HIV- positive and control groups. The results from Phase I will show whether our endotoxin neutralization system is a convenient, reproducible and inexpensive method to assess the severity of HIV disease. In Phase II of the project, we will use our system to monitor patients over a 1-2 year period to correlate endotoxin neutralization with treatment.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    150000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:150000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIODTECH, INC.
  • Organization Department
  • Organization DUNS
    170794783
  • Organization City
    NASHVILLE
  • Organization State
    AL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    352091302
  • Organization District
    UNITED STATES